Business Description
Pyxis Oncology is a Boston-based clinical-stage company focused on developing new treatments for solid tumor cancers. The company is advancing several drug candidates through clinical trials, including PYX-201 and PYX-106, both currently in Phase 1 trials, as well as PYX-107, which has reached Phase 2 testing across multiple cancer types. Pyxis works under licensing agreements with Pfizer and Biosion to develop and bring these therapies to market. Founded in 2018, the company remains in the research and development stage with no approved products yet.
